Compare INVE & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INVE | MDXH |
|---|---|---|
| Founded | 1990 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.1M | 68.7M |
| IPO Year | 1997 | 2021 |
| Metric | INVE | MDXH |
|---|---|---|
| Price | $2.39 | $0.58 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $3.55 | $1.80 |
| AVG Volume (30 Days) | 107.2K | ★ 195.2K |
| Earning Date | 11-09-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $60,219,000.00 | N/A |
| Revenue This Year | $21.08 | $5.40 |
| Revenue Next Year | $16.10 | $12.92 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.21 | N/A |
| 52 Week Low | $2.32 | $0.40 |
| 52 Week High | $5.30 | $5.33 |
| Indicator | INVE | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 38.97 | 43.94 |
| Support Level | $2.32 | $0.51 |
| Resistance Level | $3.03 | $0.75 |
| Average True Range (ATR) | 0.09 | 0.05 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 30.38 | 30.95 |
Identiv Inc develops specialty radio-frequency identification (RFID) and Internet of Things It (IoT) solutions that address customers' challenges and create new opportunities for them through the digitization and enhanced connectivity to the IoT. It designs, produces, and sells RFID and Bluetooth Low Energy (BLE) enabled devices, RFID inlays, tags, and labels that can be applied or incorporated into physical objects, providing them with a digital identity and the ability for customers to track, monitor, authenticate, and engage with consumers. Its IoT Business segment develops, manufactures, and supplies specialty IoT solutions tailored for the healthcare, logistics, smart packaging industries and other high-value end markets.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.